Psoriasis Vulgaris study: Deucravacitinib
Official title Correction of Psoriatic T Cell Signatures by Deucravacitinib
ClinicalTrials.gov ID: NCT05858645
What this study is testing
What is deucravacitinib?
an investigational oral medicine being studied as a potential treatment for moderate to severe psoriasis vulgaris is designed to block the activity of the enzyme tyrosine kinase 2 (TYK2), which helps reduce immune signaling that contributes to psoriasis
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study wants to see how the drug deucravacitinib changes the activity of immune cells in the skin and blood.
- Who it's for
- People who have a common type of psoriasis called psoriasis vulgaris.
- What's involved
- Participants will start taking the drug deucravacitinib. Doctors will test their skin and blood to check how their immune cells are working before and after treatment.
- Time commitment
- The source text does not specify the total length of the study or the number of visits required.
- Phase 4: studies an already-approved treatment
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- 18 years of age or older
- Patients with moderate-severe psoriasis (BSA \>= 10%, PASI \>=12, static Physician's Global Assessment (sPGA) 3 and above)
You likely can't join if
- taking systemic immunosuppressives in the last 12 weeks
- pregnancy
- severe immunodeficiency (either from genetic or infectious causes).
- tuberculosis or other active serious infection
- active systemic malignancy.
- breast-feeding
See the full eligibility criteria
- 18 years of age or older
- Patients with moderate-severe psoriasis (BSA \>= 10%, PASI \>=12, static Physician's Global Assessment (sPGA) 3 and above)
- taking systemic immunosuppressives in the last 12 weeks
- pregnancy
- severe immunodeficiency (either from genetic or infectious causes).
- tuberculosis or other active serious infection
- active systemic malignancy.
- breast-feeding
- Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
The study team makes the final eligibility decision.
Where it is enrolling
- San Francisco, California, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at San Francisco, California, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.